Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Brief: Cybergenics

This article was originally published in The Tan Sheet

Executive Summary

Cybergenics: Lakewood, N.J.-based weight loss and body building supplement firm files for Chapter 11 protection with U.S. bankruptcy court on Aug. 19. A prospective buyer is offering $2.5 mil. for the firm, Cybergenics says; auction sale will be held Sept. 30. Cybergenics' largest creditor is KSL Media, which is owed nearly $4.3 mil. Its other top creditors include: Ryan Drossman & Partners ($810,707), Phoenix Labs ($603,003) and Garden State Nutritionals ($441,376). As of June 30, Cybergenics' total assets were $82.9 mil. and its total liabilities were $91.7 mil., with unliquidated secured debt of $75.7 mil. and unliquidated unsecured debt of $10.1 mil. The firm had to pay $1.45 mil. in a 1994 FTC settlement over "false and unsubstantiated" product claims ("The Tan Sheet" July 25, 1994, p. 14)...

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS086015

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel